ScreenerHero

IMAImageneBio Inc. Common Stock

NAS · US · Healthcare · Biotechnology · inmagenebio.com
5.510USD-3.16%Mkt Cap: 62.55M $P/E: —

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap62.55M $
Enterprise Value-70.56M $
Revenue (TTM)0 $
Gross Profit0 $
Net Income (TTM)-45.35M $
Revenue/Share0.0000 USD
Last Price5.510 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.51
PEG—
EV/EBITDA1.21
EV/Revenue—
P/SInfinity
P/B0.45
EPS (TTM)-4.81
EPS (Forward)-3.73
52W Range
3.94014% of range15.27
52W High15.27 USD
52W Low3.940 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-5668.63%
ROE-34.06%
ROA-29.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-47.84M $
CapEx (TTM)—
FCF Margin—
FCF Yield-37.11%
Net Debt-134.24M $
Net Debt/EBITDA2.30
Balance Sheet
Debt/Equity0.02
Current Ratio21.47
Quick Ratio20.71
Book Value/Sh12.60 USD
Cash/Share11.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 28, 2025
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.00 USD
Upside (mean)+135.9%
Target Range2.000 USD – 24.00 USD
$2.000+135.9% to mean$24.00
# Analysts2
Ownership
Shares Out.11.35M
Float5.65M
Insiders12.54%
Institutions54.50%
Short Interest
Short Ratio37.8d
Short % Float3.44%
Short % Out.3.39%
Shares Short384.52K
Short (prev mo.)404.37K
Technical
SMA 505.782 (-4.7%)
SMA 2006.211 (-11.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)10.82K
Avg Vol (10d)8.44K
Technical Indicators
RSI (14)44.5
MACD-0.0280
MACD Signal-0.0171
MACD Hist.-0.0109
BB Upper5.952 USD
BB Middle5.689 USD
BB Lower5.425 USD
BB Width9.26%
ATR (14)0.3496 USD
Vol Ratio (20d)2.09x